Mundipharma submits MAA for opioid overdose reversal treatment

2 November 2016
mundipharma-logo-big

UK-based Mundipharma International has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the opioid overdose reversal treatment Nyxoid (intranasal naloxone spray).

Mundipharma’s new formulation of a drug which has been in routine practice to reverse the effects of opioid overdose for more than 40 years, is designed to support take-home naloxone programs and provide those who are first on the scene in overdose situations with an easy to use, needle-free option.

Rachel Gooch, head of addiction therapy at Mundipharma International, said: “We know that in emergency circumstances, rapid administration of a reversal agent is critical to preserving life.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical